Document:

<PAGE>

                                                                    EXHIBIT 10.3

* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

                                 AMENDMENT FOUR
                                       TO
                              DEVELOPMENT AGREEMENT
                                 ADDITIONAL WORK

         This Amendment Four made as of 13 May 2001 ("Effective Date") between
SRI International, a California, non-profit and public benefit corporation,
having a place of business located at 333 Ravenswood Avenue, Menlo Park, CA
94025 (hereinafter "SRI") and Lipid Sciences Incorporated, a Delaware
corporation, having a place of business located at 7068 Koll Center Parkway,
Suite 401, Pleasanton, CA 94566 (hereinafter "LSI").

         WHEREAS, SRI and LSI have entered into a development agreement having
an effective date of October 6, 2000 and an Amendment One thereto dated March 8,
2001 and Amendment Two dated March 28, 2001 and Amendment Three dated May 12,
2001 (hereinafter individually and collectively "Development Agreement") and
which the parties hereby amend; and

         WHEREAS, the parties intend that this Amendment Four provides for the
details of additional work, which is outside of the scope of Phase II
Development Plan of the Development Agreement.

         NOW, THEREFORE, in consideration of the premises and mutual covenants
herein contained, SRI and LSI agree as follows:

1.       For consistency and unless otherwise defined herein all initially
         capitalized terms shall have the meaning set forth in the Development
         Agreement.

2.       The scope of work and project cost, which the parties agree are outside
         of the scope of Phase II Development Plan of the Development Agreement
         are attached hereto as Exhibit A.

3.       Unless expressly amended by this Amendment Three, all other terms and
         conditions of the Development Agreement shall remain in full force and
         effect.

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date last subscribed below.

SRI:                                   LSI:
SRI International                      Lipid Sciences, Incorporated

By:    /s/ Margaret Baxter-Pearson     By:   /s/ Phil Radlick
       ---------------------------           ----------------
       Margaret Baxter-Pearson               Phil Radlick, Ph.D.
       Contracts Manager                     President & Chief Executive Officer

Date:  11/8/01                         Date: 11/13/01
      ----------------------------           --------------
<PAGE>
                                    EXHIBIT A

                                      [ * ]

                                       2<PAGE>

                                                                    EXHIBIT 10.4

* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

                                AMENDMENT FIVE TO
                              DEVELOPMENT AGREEMENT

         This Amendment Five made as of 13 May 2001 ("Effective Date") between
SRI International, a California, non-profit and public benefit corporation,
having a place of business located at 333 Ravenswood Avenue, Menlo Park, CA
94025 (hereinafter "SRI") and Lipid Sciences Incorporated, an Arizona
corporation, having a place of business located at 7068 Koll Center Parkway,
Suite 401, Pleasanton, CA 94566 (hereinafter "LSI").

         WHEREAS, SRI and LSI have entered into a development agreement having
an effective date of October 6, 2000 and an Amendment One thereto dated March 8,
2001 and Amendment Two dated March 28, 2001; Amendment Three dated May 12, 2001
and Amendment Four dated May 13, 2001 (hereinafter individually and collectively
"Development Agreement") and which the parties hereby amend; and

         WHEREAS, the parties intend that this Amendment Five provides for the
amendment of Amendment Three to reflect that LSI and SRI will compile and agree
to 90 day work plans identifying issues to be addressed and deliverables to be
met within the 90 day window and serve as the basis for work on the project
subject to the terms and conditions contained in the Development Agreement.

         NOW, THEREFORE, in consideration of the premises and mutual covenants
herein contained, SRI and LSI agree as follows:

1.       For consistency and unless otherwise defined herein all initially
         capitalized terms shall have the meaning set forth in the Development
         Agreement.

2.       Paragraph 11 of Amendment Three is revised to reflect the following
         understanding between the parties: the parties agree that going forward
         from the Effective Date hereof the parties shall mutually agree in
         writing to consecutive ninety (90) day program plans for the milestones
         stated in Appendix A of Amendment 3 of this Agreement. Each ninety-day
         plan shall be proposed and agreed upon prior to proceeding to the start
         of the next 90-day period. Each plan shall identify the issues to be
         addressed and the party responsible for addressing the issues as well
         as deliverables associated therewith. Marc Bellotti, V.P. of Product
         Development for LSI and * are each hereby authorized to act on behalf
         of LSI and SRI, respectively in all technical matters relating to the
         development of the consecutive ninety (90) day plans. The parties agree
         that the milestones listed in Exhibit A of this Agreement remain as is
         and the dates in the project development plan of June 1, 2001 shall not
         apply to this Agreement since the concurrent ninety day plans that are
         to be determined will replace them.

3.       Unless expressly amended by this Amendment Five, all other terms and
         conditions of the Development Agreement shall remain in full force and
         effect.
<PAGE>
         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date last subscribed below.

SRI:                                 LSI:
SRI International                    Lipid Sciences, Incorporated
By: /s/ V. Rene Harmount             By:  /s/ Phil Radlick
    --------------------------            ---------------------------
    V. Rene Harmount                      Phil Radlick, Ph.D.
    Group Manager, Contracts              President & Chief Executive Officer

                                       2<PAGE>

                                                                    EXHIBIT 10.5

* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

                                AMENDMENT SIX TO
                              DEVELOPMENT AGREEMENT
                         ADDITIONAL WORK-SOLVENT SENSOR

         This Amendment Six made as of 5 December, 2001 ("Effective Date")
between SRI International, a California, non-profit and public benefit
corporation, having a place of business located at 333 Ravenswood Avenue, Menlo
Park, CA 94025 (hereinafter "SRI") and Lipid Sciences Incorporated, an Arizona
corporation, having a place of business located at 7068 Koll Center Parkway,
Suite 401, Pleasanton, CA 94566 (hereinafter "LSI").

         WHEREAS, SRI and LSI have entered into a development agreement having
an effective date of October 6, 2000 and an Amendment One thereto dated March 8,
2001 and Amendment Two dated March 28, 2001; Amendment Three dated May 12, 2001;
Amendment Four dated May 13, 2001 and Amendment Five dated May 13, 2001
(hereinafter individually and collectively "Development Agreement") and which
the parties hereby amend; and

         WHEREAS, the parties intend that this Amendment Six provide for the
details of additional work related to develop a solvent sensor, which is outside
of the scope of Phase II Development Plan of the Development Agreement.

         NOW, THEREFORE, in consideration of the premises and mutual covenants
herein contained, SRI and LSI agree as follows:

1.       For consistency and unless otherwise defined herein all initially
         capitalized terms shall have the meaning set forth in the Development
         Agreement.

2.       The scope of work and project cost, which the parties agree are outside
         of the scope of Phase II Development Plan of the Development Agreement
         are attached hereto as Exhibit A.

3.       Unless expressly amended by this Amendment Six, all other terms and
         conditions of the Development Agreement shall remain in full force and
         effect.

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date last subscribed below.

SRI:                                    LSI:
SRI International                       Lipid Sciences, Incorporated

By:  /s/ V. Rene Harmount               By: /s/ Phil Radlick
     --------------------                   ----------------------
     V. Rene Harmount                       Phil Radlick, Ph.D.
     Group Manager, Contracts               President & Chief Executive Officer

<PAGE>

                                    EXHIBIT A

                                      [ * ]

                                       2<PAGE>

                                                                    EXHIBIT 10.6

                               AMENDMENT SEVEN TO
                              DEVELOPMENT AGREEMENT

         This Amendment Seven, with an effective date of October 6, 2000,
between SRI International, a California, non-profit and public benefit
corporation, having a place of business located at 333 Ravenswood Avenue, Menlo
Park, CA 94025 (hereinafter "SRI") and Lipid Sciences Incorporated, an Arizona
corporation, having a place of business located at 7068 Koll Center Parkway,
Suite 401, Pleasanton, CA 94566 (hereinafter "LSI").

         WHEREAS, SRI and LSI have entered into a development agreement having
an effective date of October 6, 2000 and An Amendment One thereto dated March 8,
2001 and Amendment Two dated March 28, 2001, Amendment Three dated May 12, 2001,
Amendment Four dated May 13, 2001, Amendment Five dated May 13, 2001 and
Amendment 6 dated 12/05/01 (hereinafter individually and collectively
"Development Agreement") and which the parties hereby amend; and

         WHEREAS, the parties intend that this Amendment Seven clarify that
Paragraph 5.1 of the Confidentiality clause includes all interactions between
the parties during the term of this Agreement.

         NOW, THEREFORE, in consideration of the premises and mutual covenants
herein contained, SRI and LSI agree as follows:

1.       For consistency and unless otherwise defined herein all initially
         capitalized terms shall have the meaning set forth in the Development
         Agreement.

2.       Paragraph 5. 1, replace line 11 through the end of the sentence on line
         12 to read: ".... in connection with the interaction between the
         parties during the term of this Agreement.." Lines 12-13: delete "To
         the extent that disclosure is authorized by this Agreement," and begin
         that sentence with "Prior to the disclosure..."

         Incorporation of the changes identified above results in Paragraph 5.1
to now read as follows:

         5.1      Confidential Information. During the term of this Agreement,
                  and five (5) years thereafter, following the expiration or
                  earlier termination hereof, each party shall exercise
                  reasonable care to maintain in confidence all information of
                  the other party (including samples) disclosed by the other
                  party and identified at the time of disclosure, to be
                  confidential ("Confidential Information"), and shall not use,
                  disclose or grant the use of the Confidential Information
                  except on a need-to-know basis to those directors, officers,
                  employees, agents, permitted sublicensces and permitted
                  assignees, to the extent such disclosure is reasonably
                  necessary in connection with the interaction between the
                  parties during the term of this

<PAGE>

                  Agreement. Prior to disclosure, each party hereto shall obtain
                  the written agreement of any such Person, who is not otherwise
                  bound by fiduciary obligations to such party, to hold in
                  confidence and not make use of the Confidential Information
                  for any purpose other than those permitted by this Agreement.
                  Each party shall notify the other promptly upon discovery of
                  the any unauthorized use or disclosure of the other party's
                  Confidential Information.

         3.       Unless expressly amended by this Amendment Seven, all other
                  terms and conditions of the Development Agreement shall remain
                  in full force and effect.

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date last subscribed below.

         SRI:                          LSI:
         SRI International             Lipid Sciences, Incorporated

         By: /s/ V. Rene Harmount      By:  /s/ Phil Radlick
             ------------------------      -----------------
             V. Rene Harmount              Phil Radlick, Ph.D.
             Group Manager, Contracts      President and Chief Executive Officer

                                       2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}]]